Association between the first 24 hours PaCO2 and all-cause mortality of patients suffering from sepsis-associated encephalopathy after ICU admission: A retrospective study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
06
2023
accepted:
08
10
2023
medline:
30
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
The relationship between the levels of the first 24-h PaCO2 and the prognosis of sepsis-associated encephalopathy (SAE) remains unclear, and the first 24-h optimal target for PaCO2 is currently inconclusive. This study was performed to investigate the correlation between PaCO2 and all-cause mortality for SAE patients, establish a reference range of the initial 24-hour PaCO2 for clinicians in critical care, and explain the possible pathophysiological mechanisms of abnormal PaCO2 levels as a higher mortality risk factor for SAE. The baseline information and clinical data of patients were extracted from the fourth edition Medical Information Mart for Intensive Care database (MIMIC-IV 2.0). Multivariate logistic regressions were performed to assess the relationship between PaCO2 and all-cause mortality of SAE. Additionally, restricted cubic splines, Kaplan-Meier Survival analyses, propensity score matching (PSM) analyses, and subgroup analyses were conducted. A total of 5471 patients were included in our cohort. In the original and matched cohort, multivariate logistic regression analysis showed that normocapnia and mild hypercapnia may be associated with a more favorable prognosis of SAE patients, and survival analysis supported the findings. In addition, a U-shaped association emerged when examining the initial 24-hour PaCO2 levels in relation to 30-day, 60-day, and 90-day mortality using restricted cubic splines, with an average cut-off value of 36.3mmHg (P for nonlinearity<0.05). Below the cut-off value, higher PaCO2 was associated with lower all-cause mortality, while above the cut-off value, higher PaCO2 was associated with higher all-cause mortality. Subsequent subgroup analyses revealed similar results for the subcohort of GCS≤8 compared to the original cohort. Additionally, when examining the subcohort of GCS>8, a L-shaped relationship between PaCO2 and the three clinical endpoints emerged, in contrast to the previously observed U-shaped pattern. The findings from the subcohort of GCS>8 suggested that patients experiencing hypocapnia had a more unfavorable prognosis, which aligns with the results obtained from corresponding multivariate logistic regression analyses. The retrospective study revealed the association between the first 24-h PaCO2 and all-cause mortality risk (30-day, 60-day, and 90-day) for patients with SAE in ICU. The range (35mmHg-50mmHg) of PaCO2 may be the optimal target for patients with SAE in clinical practice.
Identifiants
pubmed: 37874838
doi: 10.1371/journal.pone.0293256
pii: PONE-D-23-19467
pmc: PMC10597528
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293256Informations de copyright
Copyright: © 2023 Luo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Emerg Med. 2020 Oct 6;20(1):77
pubmed: 33023479
Nat Rev Immunol. 2022 Jul;22(7):444-458
pubmed: 34764472
Nat Rev Neurol. 2013 Oct;9(10):551-61
pubmed: 23999468
JAMA. 1996 Feb 14;275(6):470-3
pubmed: 8627969
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
J Crit Care. 2021 Feb;61:207-215
pubmed: 33186827
Nat Rev Neurol. 2012 Oct;8(10):557-66
pubmed: 22986430
Intensive Care Med. 2008 Sep;34(9):1676-82
pubmed: 18449528
JAMA Neurol. 2018 Jul 1;75(7):818-826
pubmed: 29554187
Neurotherapeutics. 2020 Apr;17(2):392-403
pubmed: 32378026
Chin Med J (Engl). 2012 Mar;125(5):828-31
pubmed: 22490582
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2017 Aug;43(8):1075-1084
pubmed: 28466149
Crit Care Med. 2011 Feb;39(2):305-13
pubmed: 21099426
Neurocrit Care. 2022 Oct;37(2):572-574
pubmed: 35819708
Front Neurol. 2017 Jul 17;8:250
pubmed: 28769857
Crit Care. 2010;14(2):215
pubmed: 20236459
Crit Care Clin. 1997 Jan;13(1):163-84
pubmed: 9012580
Anesthesiology. 2015 Jan;122(1):196-205
pubmed: 25401418
Crit Care. 2010;14(2):R50
pubmed: 20356365
Neurocrit Care. 2022 Apr;36(2):412-420
pubmed: 34331211
J Intensive Care Med. 2019 Nov-Dec;34(11-12):938-945
pubmed: 28718340
Neurocrit Care. 2010 Feb;12(1):35-42
pubmed: 19806473
Mol Neurobiol. 2021 Jun;58(6):2770-2779
pubmed: 33495934
Stroke. 1974 Sep-Oct;5(5):630-9
pubmed: 4472361
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Crit Care. 2019 Feb 19;23(1):54
pubmed: 30782168